POTENTIAL BENEFIT OF CURCUMIN ADJUVANT THERAPY TO THE STANDARD H. PYLORI ERADICATION THERAPY IN PATIENTS WITH PEPTIC ULCER DISEASE

Abstract

                                                                                                  Objective: This study was designed to explore the benefit of curcumin as adjuvant therapy to the standard H pylori eradication triple therapy in both duodenal and gastric ulcers patients.                       Methods: The present study enrolled 40 patients newly diagnosed endoscopically with peptic ulcer disease to be allocated into group1 treated with standard H. pylori eradication triple therapy, and group2 patients treated with curcumin (500mg) capsules three times daily for 14 day as adjuvant to standard triple therapy. Stool antigen test, immunoglobulin M serology test, tumor necrosis factor-alpha (TNF-α), interleukin 1 beta (IL1β), and total antioxidant capacity (T-AOC) are measured at the baseline and after 6 weeks of treatment.Results: The result showed that the  use of curcumin as adjuvant therapy produced highly significant improvement in healing efficacy which was significantly distinguished  in duodenal ulcer patients compared to gastric ulcer groups 2 patients (p <0.05), along with highly significant reduction in pro inflammatory IL1β level in group 2 patients(p<0.01). After 6 weeks of treatment there was highly significant elevation in level of TNF- α in groups 1 (p value <0.01), though, group 2 patients presented with non significant elevation in TNF-α level. Moreover, the total antioxidant capacity was improved with curcumin adjuvant therapy, though non- significant, compared to group 1patients who showed reduction in total antioxidant capacity.Conclusion: This study revealed that addition of curcumin as adjuvant therapy produced improvement in ulcer healing efficacy, and controlled the inflammatory and oxidative stress process induced by H pylori infection.Keywords: Peptic ulcer disease, Curcumin, H. pylori infection, inflammation and oxidation markers.